Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2011 (2011), Article ID 243465, 6 pages
Research Article

Lack of Association of Bone Morphogenetic Protein 2 Gene Haplotypes with Bone Mineral Density, Bone Loss, or Risk of Fractures in Men

1Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK
2Department of Biology, The University of York, York YO10 5YW, UK
3Department of Rheumatology, The James Cook University Hospital, Middlesbrough TS4 3BW, UK
4Human Genetics Laboratory, SSEHS, Loughborough University, Loughborough LE11 3TU, UK
5MRC Environmental Epidemiology Unit, University of Southampton, Southampton SO16 6YD, UK

Received 28 February 2011; Accepted 10 August 2011

Academic Editor: Pawel Szulc

Copyright © 2011 Satya S. Varanasi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Introduction. The association of bone morphogenetic protein 2 (BMP2) with BMD and risk of fracture was suggested by a recent linkage study, but subsequent studies have been contradictory. We report the results of a study of the relationship between BMP2 genotypes and BMD, annual change in BMD, and risk of fracture in male subjects. Materials and Methods. We tested three single-nucleotide polymorphisms (SNPs) across the BMP2 gene, including Ser37Ala SNP, in 342 Caucasian Englishmen, comprising 224 control and 118 osteoporotic subjects. Results. BMP2 SNP1 (Ser37Ala) genotypes were found to have similar low frequency in control subjects and men with osteoporosis. The major informative polymorphism, BMP2 SNP3 (Arg190Ser), showed no statistically significant association with weight, height, BMD, change in BMD at hip or lumbar spine, and risk of fracture. Conclusion. There were no genotypic or haplotypic effects of the BMP2 candidate gene on BMD, change in BMD, or fracture risk identified in this cohort.